Cargando…

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600680/ http://dx.doi.org/10.1038/sj.bjc.6604800

Ejemplares similares

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2007)

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
por: Bugat, R, et al.
Publicado: (2003)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
por: Ady, N, et al.
Publicado: (2004)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells
por: Merrouche, Yacine, et al.
Publicado: (2016)

The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
por: Piketty, A-C, et al.
Publicado: (2005)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Sialidase NEU4 is involved in glioblastoma stem cell survival
por: Silvestri, I, et al.
Publicado: (2014)

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer
por: Lindsay, C. R., et al.
Publicado: (2016)

EGF-mediated inhibition of ubiquitin-specific peptidase 24 expression has a crucial role in tumorigenesis
por: Wang, S-A, et al.
Publicado: (2017)

Anti-Neu5Gc and anti-non-Neu5Gc antibodies in healthy humans
por: Gao, Bingsi, et al.
Publicado: (2017)

Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications
por: Potti, Anil, et al.
Publicado: (2003)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Planung neu denken!
por: Schäffer, Utz, et al.
Publicado: (2020)

Verkauf neu anpacken
por: Denzel, Eberhard
Publicado: (2021)

Wild and domestic animals variably display Neu5Ac and Neu5Gc sialic acids
por: Nemanichvili, Nikoloz, et al.
Publicado: (2022)

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
por: Heudel, P-E, et al.
Publicado: (2017)

NEU1 and NEU3 enzymes alter CD22 organization on B cells
por: Ton Tran, Hanh-Thuc, et al.
Publicado: (2022)

Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival
por: Einarsdóttir, K, et al.
Publicado: (2009)

HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC)
por: Potti, Anil, et al.
Publicado: (2005)

Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor
por: Tian, X X, et al.
Publicado: (1999)

Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice.
por: Kitagawa, Y., et al.
Publicado: (1995)

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’
por: Bennouna, J, et al.
Publicado: (2006)

The effects of intracolonic EGF on mucosal growth and experimental carcinogenesis.
por: Reeves, J. R., et al.
Publicado: (1991)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Österreichische Schmerzwochen neu konzipiert
por: Stromer, Waltraud
Publicado: (2022)

Interprofessionelle Teambildung neu denken
por: Kricheldorff, Cornelia, et al.
Publicado: (2022)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor
por: Swindle, C. Scott, et al.
Publicado: (2001)

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
por: Freyer, G, et al.
Publicado: (2000)

Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy
por: Theodore, Ch, et al.
Publicado: (2004)

A case of giant hemangioma of the liver presenting with fever of unknown origin.
por: Lee, C. W., et al.
Publicado: (1994)

Targeting the EGF Receptor for Ovarian Cancer Therapy
por: Zeineldin, Reema, et al.
Publicado: (2010)

Local signaling by the EGF receptor
por: Kempiak, Stephan J., et al.
Publicado: (2003)

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
por: Delord, J-P, et al.
Publicado: (2007)

Structure aided design of a Neu5Gc specific lectin
por: Day, Christopher J., et al.
Publicado: (2017)

Absence of Neu5Gc and Presence of Anti-Neu5Gc Antibodies in Humans—An Evolutionary Perspective
por: Altman, Meghan O., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_reupvbjs5ertud8j0snt0hb932